RobynMScherberMD

PubMed

• The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence.
  Mendez Luque, L., Avelar-Barragan, J., Nguyen, H., Nguyen, J., Soyfer, E., Liu, J., Chen, J., Mehrotra, N., Huang, X., Kosiorek, H., Dueck, A., Himstead, A., Heide, E....> ;Cancer Research Communications. 2024 Mar 5
• 1 citations
  Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.
  Aaron T Gerds, Jingbo Yu, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn Scherber, Shreekant Parasuraman> ;Journal of Medical Economics. 2023 Jun 9
• 6 citations
  Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
  Gotlib, J., Castells, M., Elberink, H., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T., Panse, J., Alvarez-Twose, I., Radia, D., Tashi, T., Bulai Lividean...> ;NEJM Evidence. 2023 Jun 1
• 5 citations
  The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase.
  Mendez Luque, L., Avelar-Barragan, J., Nguyen, H., Nguyen, J., Soyfer, E., Liu, J., Chen, J., Mehrotra, N., Kosiorek, H., Dueck, A., Himstead, A., Heide, E., Lem, M., ...> ;Medrxiv. 2023 May 12
• 2 citations
  Trends in overall mortality among US veterans with primary myelofibrosis.
  Tsewang Tashi, Jingbo Yu, Shivani Pandya, Christopher Dieyi, Robyn Scherber, Shreekant Parasuraman> ;BMC Cancer. 2023 Jan 14
• Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study.
  Ellen Ritchie, Anas Al-Janadi, Craig Kessler, Robyn Scherber, Tricia Kalafut, Haobo Ren, Ruben Mesa> ;Leukemia & Lymphoma. 2022 Dec 1
• MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and ...
  Roger M Lyons, David Lessen, Salman Fazal, Robyn Scherber, Patricia Kalafut, Haobo Ren, Ellen Ritchie> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 5 citations
  MPN-103 A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera: Analysis of Data From the REVEAL Study.
  Aaron T Gerds, Ruben Mesa, John M Burke, Michael R Grunwald, Robyn Scherber, Jingbo Yu, J E Hamer-Maansson, Stephen T Oh> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
• 1 citations
  Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatme...
  Heidi E Kosiorek, Robyn M Scherber, Holly L Geyer, Srdan Verstovsek, Blake T Langlais, Gina L Mazza, Jason Gotlib, Vikas Gupta, Leslie J Padrnos, Jeanne M Palmer, Ange...> ;British Journal of Haematology. 2022 Sep 1
• 16 citations
  Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
  Naveen Pemmaraju, Aaron T Gerds, Jingbo Yu, Shreekant Parasuraman, Anne Shah, Ann Xi, Shambhavi Kumar, Robyn M Scherber, Srdan Verstovsek> ;Leukemia Research. 2022 Apr 1
• 3 citations
  Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
  Aaron T Gerds, Jingbo Yu, Robyn M Scherber, Dilan Paranagama, Jonathan K Kish, Jay Visaria, Mukul Singhal, Srdan Verstovsek, Naveen Pemmaraju> ;Acta Haematologica. 2022 Jan 1
• 23 citations
  Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
  Srdan Verstovsek, Jingbo Yu, Robyn M. Scherber, Sumit Verma, Christopher Dieyi, Chien Cheng Chen, Shreekant Parasuraman> ;Leukemia & Lymphoma. 2021 Oct 25
• 1 citations
  Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice.
  Srdan Verstovsek, Theresa Amoloja, Robyn M. Scherber, Jingbo Yu> ;Leukemia Research. 2021 Sep 22
• 2 citations
  Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care.
  Sarah Friis Christensen, Robyn M. Scherber, Gina L. Mazza, Amylou C. Dueck, Nana Brochmann, Christen Lykkegaard Andersen, Hans Carl Hasselbalch, Ruben A. Mesa, Holly L...> ;BMC Cancer. 2021 Jun 10
• 7 citations
  Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
  Leslie Padrnos, Robyn M. Scherber, H. Geyer, Blake T. Langlais, Amylou C. Dueck, Heidi E. Kosiorek, Zhenya Senyak, Matthew M. Clark, Michael Boxer, Mary Cotter, Claire...> ;Cancer Medicine. 2020 Sep 25
• 12 citations
  Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
  Sarah Friis Christensen, Robyn M. Scherber, Nana Brochmann, Martin Goros, Jonathan Gelfond, Christen Lykkegaard Andersen, Esben Meulengracht Flachs, Ruben A. Mesa> ;Cancers. 2020 Aug 6
• 16 citations
  Management of challenging myelofibrosis after JAK inhibitor failure and/or progression
  Robyn M. Scherber, Ruben A. Mesa> ;Blood Reviews. 2020 May 30
• 44 citations
  Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
  Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew T. Kuykendall, Casey O'Connell, Jamile M. Shammo, Angela G. Fleischman, Robyn M. Scherber, Rub...> ;Blood. 2020 May 7
• Assessing Symptom Burden in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Patients.
  Juan Garza, Jane Margret Anderson, Robyn M. Scherber> ;Hematology/oncology Clinics of North America. 2020 Apr 1
• 6 citations
  Elevated White Blood Cell Levels and Thrombotic Events in Patients With Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data
  Shreekant Parasuraman, Jingbo Yu, Dilan Paranagama, Sulena Shrestha, Li Wang, Onur Baser, Robyn M. Scherber> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Nov 29
• Erratum: Managing myelofibrosis (MF) that "blasts" through: Advancements in the treatment of relapsed/refractory and blast-phase MF (Hematology (United States) (2018) ...
  Robyn M. Scherber, Ruben A. Mesa> ;Hematology. American Society of Hematology. Education Program. 2019 Dec 6
• 7 citations
  Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data
  Shreekant Parasuraman, Jingbo Yu, Dilan Paranagama, Sulena Shrestha, Li Wang, Onur Baser, Robyn M. Scherber> ;Annals of Hematology. 2019 Sep 24
• 6 citations
  Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis
  Jeanne Palmer, Heidi E. Kosiorek, Christine Wolschke, Richard J. Butterfield, Holly L. Geyer, Robyn M. Scherber, Amylou C. Dueck, Allison Gathany, Ruben A. Mesa, Nicol...> ;Biology of Blood and Marrow Transplantation. 2019 Jul 6
• 6 citations
  Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions
  Prathibha Surapaneni, Robyn M. Scherber> ;Current Hematologic Malignancy Reports. 2019 Jun 1
• 2 citations
  Development of a symptom assessment in patients with myelofibrosis: Qualitative study findings
  Ruben A. Mesa, Yun Su, Adrien Woolfson, Josef T. Prchal, Kathleen Turnbull, Elias Jabbour, Robyn M. Scherber, Alan L. Shields, Meaghan Krohe, Funke Ojo, Farrah Pompilu...> ;Health and Quality of Life Outcomes. 2019 Apr 11
• Join now to see all

Journal Articles

• Reducing symptom burden in patients with myeloproliferative neoplasms in the era of JAK inhibitors to improve quality of life and prognosis  
  Mesa, RA, Scherber, RM, Geyer, HL, Leuk Lymphoma, 1/1/2015
• Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development  
  Geyer,H.,Dueck, A.C., Scherber, R.M., Mesa, RA, Mediators of Inflammation, 1/1/2015
• Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience Following FDA Approval  
  Geyer, HL, Emanuel, RM, Mesa, RA, Leukemia and Lymphoma, 1/1/2014
• Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms  
  Abelsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R, Johansson P, Leuk Lymphoma, 1/12/2013
• Ruxolitinib as an Emerging Treatment in Myelofibrosis  
  Emanuel RM, Geyer, HL, Mesa, RM, Blood and Lymphatics Cancer, 1/1/2013
• Myelofibrosis Symptoms and Management  
  Geyer HL, Emanuel RM, Mesa RA, Myeloid & Lymphoid Disorders in Practice, 1/1/2012
• Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the Treatment of Myeloproliferative Neoplasms: Implications for a JAK2 Inhibitor Era  
  Scherber, R.M., Mesa, R.A., US Oncology and Hematology, 1/1/2011
• Targeting African American Non-Smokers to Motivate Smokers to Quit: A Qualitative Inquiry  
  Thomas, JL, Scherber, R., Stewart, DW, Lynam, I, Daley, C & Ahluwalia, JS, Health Education and Behavior, 1/1/2010
• Support Needs of Overweight African American Women for Weight Loss  
  Thomas, J.L., Stewart, D.W., Lynam, I.M., Daley, C.M., Befort, C.A., Scherber, R.M., Mercurio, A.E., Okuyemi, K.S. & Ahluwalia, J.S., American Journal of Health Behavior, 1/1/2009
• Knowledge and Beliefs about Smoking among Urban African Americans with Type 2 Diabetes: A Qualitative Inquiry  
  Thomas, J.L., Stewart, D.W., Makosky, C. Befort, C.A., James, A.S., Snow, P.M., Scherber, R.M., Ahluwalia, J.S., Kansas Journal of Medicine, 1/1/2009
• Indole-3-Carbinol Inhibits (4-Methylnitrosamino) -1- butanone Plus Benzo[a]pyrene-Induced Lung Tumorigenesis in A/J Mice and Modulates Carcinogen-Induced Alterations i...  
  Kassie, F., Anderson, L.B., Scherber, R., Yu, N., Lahti, D., Upadhyaya, P., & Hecht, S.S., Cancer Research, 1/1/2007
• Join now to see all

Books/Book Chapters

• Cambridge Book 
  Chapter: Incorporating Symptomatic Assessment in Therapy Choice for Patients with Myeloproliferative Neoplasms. 
  Scherber, RM, Geyer, HL, Mesa, RA2014

Abstracts/Posters

• Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
  Robyn M. Scherber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sleep and Psychiatric Disturbance in Chronic Philadelphia Negative Myeloproliferative Neoplasms.
  Gowin, K, Langlais B, Kosiorek, HE, Dueck, A, Millstine, D, Huberty, J, Eckert, R, Padrnos, L, Scherber, RM and Mesa RA, American Society of Hematology, Atlanta, GA, 1/1/2017
• Quality of Life and Symptom Burden Among Patients with Myeloproliferative Neoplasms: Do Symptoms Impact Quality of Life?
  Langlais B, Kosiorek, H, Geyer, HL, Scherber, RM, Mesa, RA, Dueck, AC, American Society of Hematology, Atlanta, GA, 1/1/2017
• Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies.
  Padrnos, L, Kosiorek, H, Bennett R, Dueck, AC, Gowin, K, Scherber, RM, Geyer, HL, Palmer, P, Northfelt, D, Mikhael, J, Khera, N, and Mesa, RA, American Society of Hematology, Atlanta, GA, 1/1/2017
• Myeloproliferative Neoplasms and Depressive Symptoms, Diagnosis, and Associations.
  Padrnos, L, Scherber, RM, Langlais, B, Dueck, AC, Huberty, J, Geyer, HL, Gowin, K, Kosiorek, H, Bruso, M, Senyak, Z, Clark, M, Boxer, M, Cotter, M, Harrison, C, ..., American Society of Hematology, Atlanta, GA, 1/1/2017
• Nutrition and Supplement Use Characteristics in the Myeloproliferative Neoplasms: Results from the Nutrient Survey.
  Scherber, RM, Langlais, B, Padrnos, L, Palmer, J, Fleischman, AF, and Mesa, RA, American Society of Hematology, Atlanta, GA, 1/1/2017
• Psychostimulant Use Among Myeloproloferative Neoplasm Patients.
  Scherber, RM, Langlais, B, Kosiorek, H, Dueck, AC, Geyer, HL,Senyak, Z, McCallister, A, Cotter, M, VanHusen, B, Palmer, J, Padrnos, L, Harrison, C, Fleischman, AF Hube..., American Society of Hematology, Atlanta, GA, 1/1/2017
• Focus Group Study of Needs and Preferences Regarding Nutrition Among Participants with Myeloproliferative Neoplasms.
  Scherber, RM, Leproux, A, Morse, SJ, Craver, BM, Lai, Y, Dueck, A, Geyer, HL, Palmer, J, Padrnos, J, Mesa, RM, and Fleischman, AG, American Society of Hematology, Atlanta, GA, 1/1/2017
• Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE...
  Scotch, A, Scherber, RM, Bruso, M, Kosiorek, HE, Dueck, AC, Geyer, H, Fauble, VD, Vannucchi, AM, Fuentes AK, Andersen, CL, Ejerblad, E, Birgegard, G, Johansson, P..., American Society of Hematology, Atlanta, GA, 1/1/2017
• Determining Meaningful Change in the Myelofibrosis Symptom Assessment Form (MFSAF) V2.0 using a Combination of Distribution- and Anchor-based Approaches in the COMFORT...
  Dueck AC, Scherber RM, Kosiorek H, Langlais B, Padrnos L, Palmer J, Verstovsek S, Sloan J, Geyer H, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Correlations Between Inflammatory Biomarkers and Individual Symptoms Expressed by Myelofibrosis Patients in the COMFORT-I Trial: Analysis of Baseline Associations and ...
  Geyer H, Scherber RM, Kosiorek H, Verstovsek S, Langlais B, Padrnos L, Palmer J, Dueck AC, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Nutrition in Myelofibrosis: Correlates from the COMFORT-1 Study.
  Scherber RM, Geyer H, Dueck AC, Johnson C, Langlais B, Padrnos L, Palmer J, Fleischman A, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Nutritional Needs and Preferences of Myeloproliferative Neoplasm Patients: Phase IA of the NUTRIENT Study.
  Scherber RM, Geyer H, Dueck AC, Johnson C, Langlais B, Padrnos L, Palmer J, Fleischman A, Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Quality of Life Independently Predicts Overall Survival in the Myelofibrosis: Key Insights from the COMFORT-1 Study.
  Scherber RM, Kosoriek H, Geyer H, Verstovsek S, Sloan J, Langlais B, Padrnos L, Palmer J, Fleischman A, Dueck AC,Mesa R, European Hematology Association, Madrid, Spain, 1/1/2017
• Myeloproliferative Neoplasm Symptom Burden and Quality of life: Evidence of Significant Impairment Compared to Controls.
  Anderson LA, James G, Duncombe AS, Mesa RA, Scherber RM, Dueck AC, deVocht F, Clarke M, McMullin M, Hematology Association Ireland Meeting, Athlone, Ireland, 1/1/2016
• Development of an MF patient reported outcome tool for FDA Qualification: Comprehensive literature search and physician cognitive debriefing results.
  Geyer H, Kosiorek H, Dueck A, Slot S, Zweegman S, Kiladjian JJ, Boekhorst P, Schouten J, Sackmann F, Fuentes A, Scherber R, Mesa RA, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Impact of splenomegaly on MPN symptoms and association with clinical features: An analysis of the MPN QOL International Study Group.
  Geyer H, Scherber R, Kosiorek J, Dueck A, Kiladjian JJ, Slot S, Mesa RA, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Ruxolitinib compared to best avavilable therapy for essential thrombocythemia patients resistant or intoleratnt to hyroxycarbamide in MAJIC- An investigator lead rando...
  Harrison C, Mead A, Panchal A, Fox S, Yap C, Houlton A, Aliman S, Wood M, Chen F, Coppell J, Panoskaltsis N, Scherber R, Geyer H, Dueck A, Mesa R, McMullin MF, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Symptoms, Risk Classification, and Spleen Size in JAK2 Inhibitor-naïve Myelofibrosis: Implications for JAK2 Inhibitor Treatment.
  Scherber, RM, Geyer, H, Dueck, AC, Mesa, RA, European Hematology Association, Copenhagen, Denmark, 1/1/2016
• Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Ess...
  Harrison C, Mead A, Panchal A, YapC, Houlton A, Aliman S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltisis N, Knapper S, Ali S, Hamblin A, Scherber R, Geyer H, Scotch..., American Society of Hematology, San Diego, CA, 1/1/2016
• Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group.
  Scherber, RM, Geyer, H, Dueck, AC, et. al, American Society of Hematology, San Diego, CA, 1/1/2016
• Baseline Quality of Life and Symptom Burden Characteristics of Patients Intolerant to Hydroxyurea: Preliminary results from the MAJIC Trial.
  Scherber R, Fox S, Kosiorek H, Shah M, Abdi-Moradi S, Mead A, Bell H, Dueck A, Aliman S, Green A, Wood M, Ewing J, Chen F, Coppell J, Knapper S, McMullin M-F, Ktiouet ..., British Society for Haematology (BSH) Conference, Edinburgh, Scotland, 1/1/2015
• Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs.
  Geyer, HM, Scherber, RM, Dueck AC, Mesa, RM, American Society of Hematology, Orlando, FL, 1/1/2015
• Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs).
  Geyer, HM, Scherber, RM, Mesa, RM, American Society of Hematology, Orlando, FL, 1/1/2015
• Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of significant impairment compared to controls.
  Scherber, RM, Dueck, AC, Geyer, HL, Mesa, RM, American Society of Hematology, Orlando, FL, 1/1/2015
• Join now to see all

Lectures

• A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Symptom Burden and Fatigue in MPNs: Insights into Gender Differences and Non-pharmacologic Treatments. 
  Beverly Hills, CA - 1/29/2017
• MPN related symptoms and quality of life. 
  University of California, Irvine, Irvine, CA - 1/27/2017
• MPN Casebook 3: Initial Treatment Choices in MF, Risk Models and Symptom Burden. 
  Atlanta, GA - 1/18/2017
• The NUTRIENT Trial: Nutritional Needs and Preferences of Myeloproliferative Neoplasm Patients. 
  Atlanta, GA - 1/13/2017
• Symptom and Side-Effects Management: Fatigue and Chemo Brain. 
  Anaheim, CA - 1/4/2017
• Nutritional Needs and Preferences of Myeloproliferative Neoplasm Patients: The NUTRIENT Study. 
  Times Square, NY - 1/2/2017
• 2017 Update in Myeloproliferative Neoplasms. 
  Oregon Health and Science University, Portland, OR - 1/1/2017
• Setting and attaining appropriate treatment goals in polycythemia vera. 
  1/30/2016
• The importance of symptomatic assessment to optimal MPN patient management. 
  1/29/2016
• Ruxolitinib Uses and Management. 
  Seoul, South Korea - 1/28/2016
• Current and Emerging Therapy in Myelofibrosis. 
  Houston, TX - 1/1/2016
• Optimizing the management of polycythemia vera throughout the patient journey. 
  Taipei, Taiwan - 1/1/2016
• The role of ruxolitinib in the management of myelofibrosis. 
  Taipei, Taiwan - 1/1/2016
• Navigating your MPN Symptom Burden. 
  Bethesda, MD - 1/1/2016
• Practical aspects of symptom assessment in Myeloproliferative Neoplasms. 
  Milan, Italy - 1/1/2014
• Cognitive Enhancement Drug Use Among Medical Students. 
  Scottsdale, AZ - 1/1/2014
• Fatigue Among the Myeloproliferative Neoplasms 
  Scottsdale, AZ - 1/1/2014
• Join now to see all